Results 131 to 140 of about 15,364 (179)
Some of the next articles are maybe not open access.
Growth Factors, 1999
Thrombopoietin (TPO) was first described as an activity in thrombocytopenic serum that could stimulate platelet production upon transfer into other animals. The molecular cloning of TPO has allowed a detailed characterisation of its precise biological activities, both in vitro and in vivo.
C R, Underhill, R L, Basser
openaire +4 more sources
Thrombopoietin (TPO) was first described as an activity in thrombocytopenic serum that could stimulate platelet production upon transfer into other animals. The molecular cloning of TPO has allowed a detailed characterisation of its precise biological activities, both in vitro and in vivo.
C R, Underhill, R L, Basser
openaire +4 more sources
Transfusion Science, 1997
The term "thrombopoietin" (TPO) was first coined in 1958 but, despite several cytokines having thrombopoietic effects, the major megakaryocytic growth and development factor was not cloned until 1994. Wendling and colleagues (Virol, 1986; 149: 242-246) recognised a novel murine viral oncogene, v-mpl, responsible for a myeloproliferative syndrome.
+6 more sources
The term "thrombopoietin" (TPO) was first coined in 1958 but, despite several cytokines having thrombopoietic effects, the major megakaryocytic growth and development factor was not cloned until 1994. Wendling and colleagues (Virol, 1986; 149: 242-246) recognised a novel murine viral oncogene, v-mpl, responsible for a myeloproliferative syndrome.
+6 more sources
Immunology Letters, 1998
The extracellular domain of human c-Mpl, the receptor for thrombopoietin (TPO), was expressed as a chimeric protein with the interleukin-2 receptor alpha chain on the surface of murine B cell-line B300-19. BALB/c mice were immunized with cells expressing the chimeric protein.
M, Abe +8 more
openaire +2 more sources
The extracellular domain of human c-Mpl, the receptor for thrombopoietin (TPO), was expressed as a chimeric protein with the interleukin-2 receptor alpha chain on the surface of murine B cell-line B300-19. BALB/c mice were immunized with cells expressing the chimeric protein.
M, Abe +8 more
openaire +2 more sources
Thrombopoietin-receptor agonists
Current Opinion in Hematology, 2012Thrombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy. There is increasing interest to expand the role of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.In ITP, more studies are providing evidence of TPO-RA efficacy and safety, as well as their ...
Paul A, Basciano, James B, Bussel
openaire +2 more sources
2010
Megakaryopoiesis and thrombopoiesis are the central biological processes of platelet generation. Severe thrombocytopenia is a major morbidity and mortality factor in several diseases and represents a significant unmet medical need. Since the discovery of thrombopoietin (TPO) as the primary physiological regulator of megakaryopoiesis, a number of ...
openaire +2 more sources
Megakaryopoiesis and thrombopoiesis are the central biological processes of platelet generation. Severe thrombocytopenia is a major morbidity and mortality factor in several diseases and represents a significant unmet medical need. Since the discovery of thrombopoietin (TPO) as the primary physiological regulator of megakaryopoiesis, a number of ...
openaire +2 more sources
Current Opinion in Pediatrics, 1998
Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoiesis. Recent results indicate that thrombopoietin has multilineage hematopoietic effects both in vitro and in vivo. Clinical studies of thrombopoietin have begun, and are reviewed.
V C, Broudy, K, Kaushansky
openaire +2 more sources
Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoiesis. Recent results indicate that thrombopoietin has multilineage hematopoietic effects both in vitro and in vivo. Clinical studies of thrombopoietin have begun, and are reviewed.
V C, Broudy, K, Kaushansky
openaire +2 more sources
Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
Annual Review of Medicine, 2009Although the thrombopoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the development of a clinically useful TPO was hampered by the appearance of neutralizing antibodies to some forms of recombinant TPO. However, in 2008 two new drugs that mimic the effect of TPO became available to treat thrombocytopenia ...
openaire +2 more sources
Structure of Thrombopoietin and the Thrombopoietin Gene
1997The cloning of thrombopoietin (TPO) has been a significant advance for several fields of scientific inquiry. In addition to enabling the production of recombinant TPO, the cloning of TPO cDNA also facilitates examination of TPO itself, a hemopoietic cytokine with unique structural features.
Austin L. Gurney, Frederic J. de Sauvage
openaire +1 more source